Close Menu

SAN FRANCISCO - On the third day of the 38th annual JP Morgan Healthcare Conference, Puma Biotechnology provided an update on the development program for its HER2-targeted drug neratinib (Nerlynx), while Natera discussed the application of its Signatera genetic test in precision oncology trials. Below are brief reports on the presentations covered by our team at the conference and in our offices in New York.


Puma Biotechnology

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.